Presented By Luca Malorni at 2017 ASCO Annual Meeting

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

ASCO G.U Lawrence H. Einhorn.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Presented By Michael Overman at 2016 ASCO Annual Meeting

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.

MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy CCO Independent Conference.

CCO Independent Conference Coverage

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent.

A cura di Filippo de Marinis

Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer

Alessandra Gennari, MD PhD

Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*

CCO Independent Conference Coverage

CCO Independent Conference Coverage

A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.

Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Vahdat L et al. Proc SABCS 2012;Abstract P

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By John Bartlett at 2017 ASCO Annual Meeting

SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,

Swain SM et al. Proc SABCS 2012;Abstract P

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Metastatic HER2+ Breast Cancer: Resistance

Intervista a Angelo Delmonte

Evolving Paradigms in the Management of HR-Positive Breast Cancer

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

Overall Program Goals. Overall Program Goals Current Approaches.

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Barrios C et al. SABCS 2009;Abstract 46.

Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.

CDK4/6 Inhibitors in Breast Cancer:

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Krop I et al. SABCS 2009;Abstract 5090.

CDK4/6 Inhibitors in Practice

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Treatment of HR+ Breast Cancer: A Clinical Update

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Hormone Receptor-Positive Advanced Breast Cancer:

Baselga J et al. SABCS 2009;Abstract 45.

The Road to Quality Improvement in HER2-Positive Breast Cancer

Hormone Receptor-Positive Advanced Breast Cancer Introduction

Introduction Advanced Hormone Receptor-Positive Breast Cancer

New Paradigms in HR-Positive Advanced Breast Cancer

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

Martin M et al. Proc SABCS 2012;Abstract S1-7.

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

CDK4/6 Inhibitors.

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Presented By Joshua Richter at 2016 ASCO Annual Meeting

Authors: Sunil Verma Date posted: December 22, 2008

Presentation transcript:

Presented By Luca Malorni at 2017 ASCO Annual Meeting A phase II trial of the CDK4/6 inhibitor Palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2–) metastatic breast cancer (mBC) (TREnd trial) Presented By Luca Malorni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting Background Presented By Luca Malorni at 2017 ASCO Annual Meeting

To Reverse Endocrine resistance (TREnd) trial: aims Presented By Luca Malorni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting TREnd study design Presented By Luca Malorni at 2017 ASCO Annual Meeting

Study endpoints and statistical assumptions Presented By Luca Malorni at 2017 ASCO Annual Meeting

Baseline pts characteristics Presented By Luca Malorni at 2017 ASCO Annual Meeting

Prior treatment for mBC Presented By Luca Malorni at 2017 ASCO Annual Meeting

Study treatment administration and dose intensity Presented By Luca Malorni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting Slide 9 Presented By Luca Malorni at 2017 ASCO Annual Meeting

Duration of Clinical Benefit Presented By Luca Malorni at 2017 ASCO Annual Meeting

Progression free survival (PFS) Presented By Luca Malorni at 2017 ASCO Annual Meeting

PFS by duration of prior ET Presented By Luca Malorni at 2017 ASCO Annual Meeting

Selected adverse events Presented By Luca Malorni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting Conclusions Presented By Luca Malorni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting Acknowledgements Presented By Luca Malorni at 2017 ASCO Annual Meeting